Lu-Ann Murdoch
ARTICLES BY THIS AUTHOR
- 11/24/2024
First needleless device for insulin administration now available in Canada
InsuJet, a needle-free insulin injection system, uses jet-injection technology to deliver insulin subcutaneously in persons six years of age or older. - 11/20/2024
Preventing respiratory syncytial virus (RSV) infection in young children
Canadian Paediatric Society issues guidance on respiratory syncytial virus (RSV) prevention strategies in young children for the 2024-2025 viral respiratory illness season. - 11/19/2024
POP QUIZ: Migraine prevention
The Canadian Headache Society has issued updated (2024) guidelines for the prevention of episodic and chronic migraine. - 11/19/2024
Tirzepatide reduces body weight and slows progression to diabetes in patients with obesity and prediabetes
Three-year study shows significant and sustained weight reduction with tirzepatide and a markedly lower risk of progression from prediabetes to type 2 diabetes. - 11/13/2024
Updated Canadian guidelines for prevention of episodic and chronic migraine
Canadian Headache Society updates the migraine prevention guidelines, incorporating newer therapies and adding guidance on preventing chronic migraine. - 11/11/2024
Update to Canadian clinical practice guideline for management of opioid use disorder
Methadone or buprenorphine should be considered as standard first-line treatment for opioid use disorder, with slow-release oral morphine as a second-line treatment option. - 11/10/2024
Drug News—October 2024
A review of new launches, new indications, new dosage forms and Health Canada advisories. - 11/6/2024
New Canadian consensus recommendations for managing chronic insomnia
A multidisciplinary panel of Canadian experts in sleep medicine and insomnia has developed consensus recommendations based on evidence and practical experience. - 11/5/2024
POP QUIZ: Listeria
News reports of Listeria outbreaks and Listeria-related product recalls are drawing greater attention to this bacterial illness. - 11/4/2024
Semaglutide may benefit patients with knee osteoarthritis pain and obesity
Multicentre trial shows semaglutide reduces body weight, knee pain and analgesic use, and improves physical function in patients with obesity and knee osteoarthritis pain.
